Screener
Kymera Therapeutics KYMR Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Right-of-use assets, operating leases | 41,100 | 42,351 |
| Other non-current assets | 7,385 | 9,114 |
| Restricted cash | 5,822 | 5,800 |
| Total assets | $1,645,444 | $1,742,812 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $8,918 | $4,015 |
| Accrued expenses (Note 8) | 48,476 | 42,274 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's total assets?
- Kymera Therapeutics (KYMR) reported total assets of $1.65B in Q2 2026.
- How has Kymera Therapeutics's total assets changed year-over-year?
- Kymera Therapeutics's total assets increased by 45.5% year-over-year, from $1.13B to $1.65B.
- What is the long-term trend for Kymera Therapeutics's total assets?
- Over 5 years (2020 to 2025), Kymera Therapeutics's total assets has grown at a 29.0% compound annual growth rate (CAGR), from $487.18M to $1.74B.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Kymera Therapeutics's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude